PROSTATIC NEOPLASMS

This study tests a new type of radiation (SBRT) that targets only the tumor in the prostate, not the whole gland. The goal is to cure early-stage prostate cancer while reducing side effects like incontinence and impotence. About 42 men with low- or intermediate-risk cancer that h…

This study tests a new radioactive drug (177Lu-rhPSMA-10.1) in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to find the safest and most effective dose to shrink tumors or lower PSA levels. About 82 men will take part acr…

This early-stage study tests a new drug combination for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The treatment uses a T-cell redirecting agent (pasritamig) plus an A2a receptor blocker to help the immune system attack c…

This study tests a new medicine called ifinatamab deruxtecan (I-DXd) against standard chemotherapy (docetaxel) in people with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and no longer responds to hormone therapy. About 1,440 …

This early-stage study tests a combination of two experimental drugs for men with a type of advanced prostate cancer that no longer responds to hormone therapy. The first drug is designed to direct the body's immune T-cells to attack cancer cells, while the second delivers a toxi…

This early-phase study tests a new drug called DM002 in 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by testing low to higher doses in small groups; second, giving t…

This study tests a new drug called pocenbrodib, either by itself or combined with other treatments, in people with a type of advanced prostate cancer that no longer responds to hormone therapy. The goal is to find the safest dose and see if it helps shrink tumors or lower PSA lev…

This study tests a new drug called opevesostat (plus hormone replacement therapy) against two standard drugs (abiraterone or enzalutamide) in men with metastatic castration-resistant prostate cancer that got worse after one prior hormone treatment. About 1,314 participants will b…

This early-phase study tests two experimental drugs (JNJ-87189401 and JNJ-78278343) that help the immune system attack prostate cancer cells. About 355 adults with advanced prostate cancer will take part. The main goal is to find the safest dose and check for side effects.

This study tests a new type of PET scan using a radioactive tracer called 64Cu-SAR-bisPSMA to see if it can better detect prostate cancer that has spread to nearby lymph nodes. About 383 men with high-risk prostate cancer who are planning to have their prostate removed will get t…

This study looks at whether adding a special PET/CT scan (rhPSMA-7.3) to the usual MRI can better find aggressive prostate cancer in men with low-risk cancer who are monitoring their disease. About 120 men will get both scans before a confirmatory biopsy. The goal is to see if th…

This study tests a new type of radiation therapy that adjusts the treatment each day based on changes in the patient's body. The goal is to safely reduce the amount of healthy tissue exposed to radiation, which may lower side effects. The study involves 130 men with prostate canc…

This study tests whether acupuncture can reduce hot flashes and improve sleep and quality of life in men receiving hormone therapy for prostate cancer. Twenty-four men will be randomly assigned to start acupuncture right away or after a delay, and all will receive standard lifest…

This study looks at whether a low to moderate load power training program can improve quality of life, strength, and balance in men with metastatic prostate cancer who are on hormone therapy. About 66 participants will either join a supervised exercise program twice a week for 6 …

This study collects blood samples from 1,000 men with prostate cancer to look for genetic differences that may explain why some cancers stop responding to hormone therapy. Participants give blood during clinic visits, and researchers analyze DNA and other genetic material. The go…

This study follows 400 people who have urologic cancer surgery with lymph node removal to see how often leg swelling (lymphedema) happens. Researchers use questionnaires and special devices to measure swelling and tissue fluid over two years. The goal is to better understand this…

This study follows 500 men aged 30–75 who have specific genetic changes linked to a higher risk of prostate cancer but have not been diagnosed. Researchers will track their health over time using yearly checkups, blood tests, and MRI scans to learn how these genes affect cancer r…

This study observes how men with metastatic hormone-sensitive prostate cancer (mHSPC) are treated with darolutamide in everyday urology clinics across the US. Researchers will review medical records of about 1,400 patients to understand who gets which treatment (darolutamide with…

This study tracks 270 men with advanced prostate cancer that has spread but still responds to hormone therapy. Researchers want to see how faithfully patients take their apalutamide pills over the first year. The goal is to understand which patients might struggle with adherence …

This study follows 3,000 men with low-risk prostate cancer who chose active surveillance (close monitoring instead of immediate treatment). Researchers aim to find biological markers that can tell apart aggressive cancers from slow-growing ones. Participants provide regular blood…

This study looks at why some prostate cancers return after radiation treatment. Researchers will use detailed MRI scans and tissue samples to see how tumors respond to radiation. The goal is to better understand treatment failures and help doctors choose the best next steps for e…